The metabolic syndrome - A controversial diagnostic concept;Das metabolisches syndrom - Ein umstrittenes diagnostisches konzept

Herz

Volumn 32, Issue 7, 2007, Pages 529-540

  Moebus, Susanne ^a   Stang, Andreas ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Epidemiology; Metabolic syndrome; Risk factor; Risk prediction

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIMARY MEDICAL CARE; REVIEW;

DIAGNOSIS, DIFFERENTIAL; GERMANY; HUMANS; METABOLIC SYNDROME X; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 35848945662     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-007-3025-9     Document Type: Review

References (87)

1. Gesundheitsberichterstattung des Bundes. Gesundheit in Deutschland. Berlin: Robert Koch-Institut, 2006:117-8.
2. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
3. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease [Erratum in: Diabetes Care 2005;28:238]? Diabetes Care 2004;27:2676-81.
4. Balkau B, Eschwege E. The metabolic syndrome. Lancet 2005;366:1921-4.
5. Greenland P. Critical questions about the metabolic syndrome. Circulation 2005;112:3675-6.
6. Slama G, Balkau B, Valensi P. Comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2007;50:1354-5.
7. Ferrannini E. Response to comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2007;50:1356-7.
8. Reaven G. The metabolic syndrome: is this diagnosis necessary [Erratum in: Am J Clin Nutr 2006;84:1253]? Am J Clin Nutr 2006;83:1237-47.
9. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome. Lancet 2005;366:1921-2.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
11. DGK. Pressemeldung. Düsseldorf: DGK, 2005 (http://www. innovations-report.de/html/berichte/medizin_gesundheit/bericht-50054.html).
12. Khunti K, Davies M. Metabolic syndrome. BMJ 2005;331:1153-4.
13. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006;83:1248-51.
14. Howard WJ. The metabolic syndrome: is a critical appraisal really necessary? The point of view of a practicing physician. Nutr Metab Cardiovasc Dis 2006;16:85-7.
15. Grant PJ, McGuire DK. The metabolic syndrome: "to be or not to be, that is the question". Diabet Med 2006;23:16-8.
16. Beaser RS, Levy P. A work in progress, but a useful construct. Circulation 2007;115:1812-8.
17. Zimmet P., 2007. Pressemitteilung: http://www.innovations-report.de/ html/berichte/medizin_gesundheit/bericht-43048.html).
18. Hanefeld M, Metzler W, Kohler C, et al. [Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy.] Herz 2006;31:246-54.
19. Hanefeld M, Schaper F, Ceriello A. Geschichte und Definition(en) des metabolischen Syndroms. Internist (Berl) 2007;48:117-25.
20. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 1998;20:157-72.
21. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
23. Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dtsch Gesundheitswesen 1981;36:545-51.
24. Eckel RH, Kahn R, Robertson RM, et al. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006;29:1697-9.
25. Beckley ET. New ADA initiative moves beyond "metabolic syndrome". DOC News 2006;3:1-19.
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
27. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association. Circulation 2004;109:433-8.
28. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrom. Brussels: International Diabetes Federation (IDF), 2005 (http://www.idf.org).
29. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
30. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
31. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
32. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
33. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004;59:207-23.
34. Franks PW, Olsson T. Metabolic syndrome and early death: getting to the heart of the problem. Hypertension 2007;49:10-2.
35. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598-615.
36. Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 1992;3:434-40.
37. Jorgensen ME, Borch-Johnsen K. The metabolic syndrome - is one global definition possible? Diabet Med 2004;21:1064-5.
38. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003;73:2395-411.
39. Tikhonoff V, Casiglia E. Metabolic syndrome: nothing more than a constellation? Eur Heart J 2007;28:780-1.
40. Neuhauser HK, Ellert U. Prävalenz des metabolischen Syndroms in Deutschland: eine Sensitivitätsanalyse. Präsentiert beim gms german medical science Meeting, Freiburg, 12.-15.09.2005.abstract (http://www.egms. de/en/meetings/gmds2005/05gmds183.shtml).
41. Moebus S, Hanisch JU, Neuhaeuser M, et al. Assessing the prevalence of the metabolic syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. GMS Ger Med Sci 2006;4:Doc07 (http://www.egms.de/en/gms/2006- 4/000036.sthml).
42. Villegas R, Perry IJ, Creagh D, et al. Prevalence of the metabolic syndrome in middle-aged men and women. Diabetes Care 2003;26:3198-9.
43. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007;49:40-7.
44. Hillier TA, Rousseau A, Lange C, et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia 2006;49:1528-35.
45. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-405.
46. Lee WY, Park JS, Noh SY, et al. Prevalence of the metabolic syndrome among 40,698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;65:143-9.
47. Ko GT, Cockram CS, Chow CC, et al. High prevalence of metabolic syndrome in Hong Kong Chinese - comparison of three diagnostic criteria. Diabetes Res Clin Pract 2005;69:160-8.
48. Al Lawati JA, Mohammed AJ, Al Hinai HQ, et al. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 2003;26:1781-5.
49. Athyros V, Bouloukos V, Pehlivanidis A, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005;7:397-405.
50. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
51. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-9.
52. Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003;61:29-37.
53. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006;49:41-8.
54. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
55. Katzmarzyk PT, Janssen I, Ross R, et al. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care 2006;29:404-9.
56. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003;11:1480-7.
57. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005;28:2745-9.
58. Kim MH, Kim MK, Choi BY, et al. Educational disparities in the metabolic syndrome in a rapidly changing society - the case of South Korea. Int J Epidemiol 2005;34:1266-73.
59. Silventoinen K, Pankow J, Jousilahti P, et al. Educational inequalities in the metabolic syndrome and coronary heart disease among middle-aged men and women. Int J Epidemiol 2005;34:327-34.
60. Sundstrom J, Riserus U, Byberg L, et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878-82.
61. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
62. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
63. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41.
64. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
65. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78.
66. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1:1373-6.
67. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
68. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk In Communities study. Diabetes Care 2005;28:385-90.
69. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-50.
70. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857-64.
71. Mitka M. Metabolic syndrome recasts old cardiac, diabetes risk factors as a "new" entity. JAMA 2004;291:2062-3.
72. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47:201-10.
73. Meigs JB, Williams K, Sullivan LM, et al. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004;27:1417-26.
74. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
75. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995;44:369-74.
76. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
77. Blaha M, Elasy TA. Clinical use of the metabolic syndrome: why the confusion? Clin Diabetes 2006;24:125-31.
78. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007;115:1806-11.
79. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94.
80. Laakso M, Kovanen PT. Metabolic syndrome: to be or not to be? Ann Medicine 2006;38:32-3.
81. Bogardus C, Lillioja S, Mott DM, et al. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol Endocrinol Metab 1985;248:E286-91.
82. Kim SH, Chunawala L, Linde R, et al. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose - impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol 2006;48:293-7.
83. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), final report. Circulation 2002;106:3143.
84. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-5.
85. Keil U, Fitzgerald AP, Gohlke H, et al. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen: die neuen SCORE-Deutschland-Tabellen für die Primärprävention. Dtsch Ärztebl 2005;102:A1808-12.
86. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
87. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9: 237-52.